These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 5055013)

  • 1. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect?
    Barjon P; Fourcade J; Mimran A; Charra B
    Rev Eur Etud Clin Biol; 1972 Feb; 17(2):187-92. PubMed ID: 5055013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 3. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 4. [Catecholamine excretion and treatment of parkinsonism with midantan].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1323-6. PubMed ID: 1015136
    [No Abstract]   [Full Text] [Related]  

  • 5. A hort-term evaluation of L-dopa therapy in 34 patients with parkinsonism.
    Mones RJ; Elizan TS
    J Mt Sinai Hosp N Y; 1969; 36(6):503-15. PubMed ID: 5261089
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of parkinsonism with L-dopa].
    Chouza C; Marín C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1970; 16(1):170-83. PubMed ID: 5538052
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of parkinsonism with L-dopa].
    Hernández Peniche J; Martínez Villar C; De León Charles C
    Rev Invest Clin; 1971; 23(2):125-32. PubMed ID: 5114336
    [No Abstract]   [Full Text] [Related]  

  • 10. [L-Dopa in parkinsonism, myth or reality].
    Henry P
    Bord Med; 1970 Feb; 3(2):393-7. PubMed ID: 5425873
    [No Abstract]   [Full Text] [Related]  

  • 11. L-dopa metabolism in man (with special reference to parkinsonism).
    Sandler M
    Sci Basis Med Annu Rev; 1972; ():161-73. PubMed ID: 4564341
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preliminary results of the treatment with L-Dopa of 30 patients with Parkinsonism].
    Dumas R; Rahme M; Schott B
    J Med Lyon; 1971 Apr; 52(207):599-615. PubMed ID: 5136571
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of parkinsonism with L-dopa].
    Presthus J
    Nord Med; 1970 Nov; 84(46):1467-8. PubMed ID: 5479940
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa in the treatment of Parkinsonism.
    Brezný I; Buranová D; Cernácek J; Trávniková M
    Act Nerv Super (Praha); 1972; 14(2):96. PubMed ID: 5040182
    [No Abstract]   [Full Text] [Related]  

  • 16. [Results of treatment of Parkinsonism with L-dopa].
    De Divitiis E; D'Andrea F; Signorelli CD
    Sist Nerv; 1970; 22(2):99-108. PubMed ID: 5504563
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa and parkinsonism.
    Okihiro MM
    Hawaii Med J; 1971; 30(5):390-2. PubMed ID: 5160226
    [No Abstract]   [Full Text] [Related]  

  • 18. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 19. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation].
    Antonini F; Baroni A; Roveyaz L
    Sist Nerv; 1970; 22(2):74-81. PubMed ID: 5504560
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.